Abstract:Fusion of the HIV envelope with the target cell membrane is a critical step of HIV entry into the target cell. The HIV envelope glycoprotein gp41 plays an important role in the fusion of viral and target cell membranes and serves as an attractive target for development of HIV fusion inhibitors. The extracellular domain of gp41 contains three important functional regions, i.e. fusion peptide (FP), N- and C-terminal heptad repeats (NHR and CHR, respectively). The FP region is composed of hydrophobic, glycine-rich residues that are essential for the initial penetration of the target cell membrane. NHR and CHR regions consist of hydrophobic residues, which have the tendency to form alpha-helical coiled coils. During the process of fusion of HIV or HIV-infected cells with uninfected cells, FP inserts into the target cell membrane and subsequently the NHR and CHR regions change conformations and associate with each other to form a fusion-active gp41 core. Peptides derived from NHR and CHR regions, designated N- and C-peptides, respectively, have potent inhibitory activity against HIV fusion by binding to the CHR and NHR regions, respectively, to prevent the formation of the fusion-active gp41 core. C-peptide may also bind to FP, thereby blocking its insertion into the target cell membrane. One of the C-peptides, T-20, which is in the phase III clinical trials, has potent in vivo activity against HIV infection and is expected to become the first peptide HIV fusion inhibitory drug in the near future. However, this peptide HIV fusion inhibitor lacks oral availability and is sensitive to the proteolytic digestion. Therefore, it is essential to develop small molecular non-peptide HIV fusion inhibitors having a mechanism of action similar to the C-peptides. One of the approaches in identifying the inhibitors is to use an immunological assay to screen chemical libraries for the compounds that potentially block the interaction between the NHR and CHR regions to form a fusion-active gp41 core. In combination with computer-aided molecular docking techniques, the first active non-peptide HIV fusion inhibitor targeting gp41, ADS-J1, was identified. Other potential candidates of non-peptide HIV fusion inhibitors have also been identified using different approaches. It is expected that both peptide and non-peptide HIV fusion inhibitors will be developed as new classes of anti-HIV drugs, which will be used alone or in combination with HIV reverse transcriptase and protease inhibitors, for the treatment of HIV infection and AIDS.

Two Partially Overlapping Antiviral Peptides from the External Portion of HIV Type 1 Glycoprotein 41, Adjoining the Transmembrane Region, Affect the Glycoprotein 41 Fusion Domain

Short Communication: in VitroSynergy Between Peptides or Neutralizing Antibodies Targeting the N- and C-Terminal Heptad Repeats of HIV Type 1 Gp41

Correction: HIV-1 Fusion is Blocked Through Binding of GB Virus C E2D Peptides to the HIV-1 Gp41 Disulfide Loop.

HIV Entry Inhibitors Targeting Gp41: from Polypeptides to Small-Molecule Compounds

Affinity maturation and characterization of a human monoclonal antibody against HIV-1 gp41.

Design, Synthesis and Activity Evaluation of Novel Peptide Fusion Inhibitors Targeting HIV-1 Gp41

Inhibition of HIV-1 infection by a fusion domain binding peptide from the HIV-1 envelope glycoprotein GP41.

HIV-1 Gp41 Fusion Intermediate: a Target for HIV Therapeutics.

A “Two-Birds-One-Stone” Approach toward the Design of Bifunctional Human Immunodeficiency Virus Type 1 Entry Inhibitors Targeting the CCR5 Coreceptor and gp41 N-Terminal Heptad Repeat Region

Identification Of A Critical Motif For The Human Immunodeficiency Virus Type 1 (Hiv-1) Gp41 Core Structure: Implications For Designing Novel Anti-Hiv Fusion Inhibitors

HIV Gp41 C-terminal Heptad Repeat Contains Multifunctional Domains: RELATION TO MECHANISMS OF ACTION OF ANTI-HIV PEPTIDES

An Artificial Peptide-Based Bifunctional HIV-1 Entry Inhibitor That Interferes with Viral Glycoprotein-41 Six-Helix Bundle Formation and Antagonizes CCR5 on the Host Cell Membrane

Helical Interactions in the HIV-1 Gp41 Core Reveal Structural Basis for the Inhibitory Activity of Gp41 Peptides.

Type-specific and Cross-Reactive Neutralizing Antisera Against HIV Elicited by V3-peptide Heptalysine Octomers.

P848 Revisiting Enfuvirtide’s Mechanism and Designing Its Analog with Improved Activity by Targeting Triple Sites in Gp41

Design of artificial α-helical peptides targeting both gp41 deep pocket and subpocket as potent HIV-1 fusion inhibitors

HIV-1 Gp41-Targeting Fusion Inhibitory Peptides Enhance the Gp120-Targeting Protein-Mediated Inactivation of HIV-1 Virions

A Salt Bridge Between An N-Terminal Coiled Coil Of Gp41 And An Antiviral Agent Targeted To The Gp41 Cove Is Important For Anti-Hiv-1 Activity

Fusion Peptide of HIV-1 As a Site of Vulnerability to Neutralizing Antibody

Peptide and Non-peptide HIV Fusion Inhibitors

Novel Recombinant Engineered Gp41 N-terminal Heptad Repeat Trimers and Their Potential As Anti-Hiv-1 Therapeutics or Microbicides.